What's in Institut Claudius Regaud's pipeline?

Institut Claudius Regaud has 5 drugs in our index: 3 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Institut Claudius Regaud's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/institut-claudius-regaud.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Institut Claudius Regaud — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Institut Claudius Regaud pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Pharmacokinetics blood samples	Pharmacokinetics blood samples	marketed
Tamoxifen, Letrozole , Anastrozole, Exemestane	Tamoxifen, Letrozole , Anastrozole, Exemestane	marketed
Tamoxifen, Letrozole, Anastrozole or Exemestane	Tamoxifen, Letrozole, Anastrozole or Exemestane	marketed	Estrogen receptor antagonist (tamoxifen); Aromatase inhibitor (letrozole, anastrozole, exemestane)	Estrogen receptor alpha (tamoxifen); Aromatase/CYP19A1 (letrozole, anastrozole, exemestane)	Oncology

Therapeutic area mix

Oncology · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Institut Claudius Regaud:

Cite this brief

Drug Landscape (2026). Institut Claudius Regaud — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/institut-claudius-regaud. Accessed 2026-06-10.